At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
Minocyclinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open Label Study to Document the Treatment Effect of 1 and 2% BPX-01 Minocycline Topical Gel in Moderate to Severe Inflammatory Non-nodular Acne Vulgaris (Protocol Number BPX-01-C04)
In Brief
A Phase 2 clinical trial evaluating Minocycline for Acne Vulgaris. Completed, enrolled 20 participants across 2 sites.
Detailed Summary
This is a multi center open label study intended to provide photo documentation and time to response data for BPX-01 1 and 2% minocycline topical gel for the treatment of moderate to severe non-nodular inflammatory acne vulgarism.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcne Vulgaris
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartMar 2017
Primary CompletionJun 2018
TodayJul 2026
First PostedOct 27, 2016
Enrollment StartMar 13, 2017
Primary CompletionJun 1, 2018
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.7 years ago
Interventions
Minocyclinedrug
BPX-01 1 or 2% topical gel will be applied to face once daily